Recursion Pharmaceuticals Cash Flow Statement
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Recursion Pharmaceuticals free cash flow
In fiscal 2025, Recursion Pharmaceuticals generated -$371.8 million of operating cash flow and spent $6.5 million on capital expenditures. That left free cash flow of -$378.3 million, a free-cash-flow margin of -506.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Recursion Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -644.76M | -463.66M | -328.07M | -239.48M | -186.48M | -87.01M | -61.88M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 83.70M | 36.49M | 24.40M | 11.76M | 8.40M | 3.94M | 2.49M |
| Stock-Based Compensation | 111.22M | 81.69M | 53.50M | 27.91M | 14.84M | 4.29M | 1.39M |
| Change in Working Capital | -6.45M | -27.67M | -49.82M | 112.08M | -13.52M | 25.36M | 265.00K |
| Operating Cash Flow | -371.81M | -359.17M | -287.78M | -83.52M | -158.61M | -45.40M | -57.04M |
| Capital Expenditures | -6.47M | -13.70M | -11.96M | -37.06M | -39.80M | -5.83M | -3.91M |
| Investing Cash Flow | -16.87M | 260.06M | -10.23M | 193.25M | -271.74M | -8.74M | -3.91M |
| Debt Repaid | -8.43M | -4.44M | -766.00K | -90.00K | -12.80M | -77.00K | -11.18M |
| Financing Cash Flow | 521.53M | 304.12M | 140.13M | 154.34M | 458.54M | 246.13M | 120.41M |
| Net Change in Cash | 150.90M | 201.60M | -157.69M | 263.76M | 28.18M | 192.00M | 59.46M |
| Free Cash Flow | -378.28M | -372.87M | -299.74M | -120.58M | -198.41M | -51.23M | -60.95M |
This table shows 7 annual periods of Recursion Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2019, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RXRX's reporting calendar. What is a cash flow statement?